SK Bioscience Co

SK Bioscience Co Intangible Assets

The Intangible Assets of SK Bioscience Co (302440.KS) as of Nov 3, 2026 is 67.11 B KRW. In the previous year, Intangible Assets was 22.46 B KRW — a change of 198.82% (higher).

Intangible Assets

67.11 BKRW

YoY

198.82%

Last updated:

Intangible Assets of SK Bioscience Co is 2024 67.11 B KRW. Intangible Assets of SK Bioscience Co was 2023 22.46 B KRW. It decreases by 198.82% higher compared to the previous year.

The SK Bioscience Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
21.84 B KRW
Jan 1, 2019
19.48 B KRW
Jan 1, 2020
17.86 B KRW
Jan 1, 2021
17.06 B KRW
Jan 1, 2022
18.18 B KRW
Jan 1, 2023
22.46 B KRW
Jan 1, 2024
67.11 B KRW
The SK Bioscience Co Intangible Assets history
YEARIntangible AssetsYoY
67.11 BKRW+198.82%
22.46 BKRW+23.53%
18.18 BKRW+6.56%
17.06 BKRW-4.46%
17.86 BKRW-8.32%
19.48 BKRW-10.81%
21.84 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

Intangible Assets of SK Bioscience Co is 67.11 B KRW in 2024.

Intangible Assets of SK Bioscience Co changed from 22.46 B KRW to 67.11 B KRW, representing a 198.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's SK Bioscience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SK Bioscience Co

All Key Metrics — SK Bioscience Co